Definium Therapeutics Shares Surge 60% on Late-Stage Depression Drug Data

Q: With a 24% remission rate, is this 'miracle' drug a real cure or just a marginal improvement?

It is not a cure, but it is more than a marginal improvement. The key number is not just the 24% remission rate by Week 6, but the gap versus placebo: 24% for DT120 against 3% for placebo in a randomized Phase 3 trial. That 21-point difference is large for depression research, especially after a single dose. The drug also produced an 8.1-point placebo-adjusted improvement on the MADRS depression scale at six weeks, with effects appearing as early as Week 1 and largely holding through Week 12. That said, “miracle” is too strong. A 24% remission rate still means most patients did not reach remission by six weeks. Major depressive disorder is a chronic, relapsing illness, and remission in one trial is not the same as a permanent cure. Longer follow-up, replication, and real-world data will matter. What makes the result notable is the context. Many standard antidepressants are slower, and patients who have already failed conventional treatment often have low odds of remission. Analysts and investigators are calling DT120 potentially “best-in-class” because of the speed, durability and safety profile seen so far, not because it cures everyone. The fairest reading is that DT120 looks like a clinically meaningful advance, particularly for hard-to-treat patients, but not a definitive cure. The excitement is justified by the size and speed of the benefit, while the limits are clear in the remission rate itself.

1 articles · Updated · Bloomberg · Jun 22

Definium Therapeutics jumped as much as 60% Monday after releasing late-stage trial results that the company described as groundbreaking for its experimental treatment for major depressive disorder.
The rally was driven by investor optimism that the psychedelic-based therapy could stand out in a hard-to-treat market, especially for patients who have not benefited from conventional options.
Piper Sandler analyst David Amsellem said the new data reinforced his view that the drug could emerge as a best-in-class treatment.
The move puts Definium among the latest psychedelic drug developers to win market support on clinical progress, with future focus likely shifting to regulatory and commercialization steps.